Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

PLAD, Inc. Retires 200 Million Common Shares

Posted on: 01 Nov 16

PR Newswire

ROCKLEDGE, Fla., Nov. 1, 2016

ROCKLEDGE, Fla., Nov. 1, 2016 /PRNewswire/ -- PLAD, Inc. (OTC Pink: PLAD), a newly formed company that plans to bring to market a new premium hemp seed coffee blend, Hemp water products and supplements that will focus on the Health and Fitness markets, announces it has retired Two Hundred Million (200,000,000) shares of its Common Stock.

The Company recently announced it acquired all of the membership interest in Elev8 Hemp LLC from Kona Gold Solutions, Inc. (OTC.PK:KGKG) in exchange for Two Hundred Thousand Dollars ($200,000), to be paid in a combination of stock and cash.

About Elev8 Hemp LLC:

Elev8 Hemp LLC is a newly formed company that plans to bring to market a new premium hemp seed coffee blend. Sipp Industries will be exclusively providing to Elev8 Hemp "proprietary hemp ingredients" for the development of their new hemp coffee brand. Elev8 Hemp Seed Coffee will be the result of the blending of roasted, organic hemp seeds with roasted, organic, Fair Trade Mexican coffee beans that produces a premium, delicious, full-flavored hemp seed coffee that does not leave a bitter after-taste.

The Company is still in the process of requesting a name and symbol change. The new name (once approved) will be Elev8 Brands, Inc. and will apply to trade under a new symbol (OTC.PK: VATE). 

Please visit, for more information. 

Safe Harbor Statement:

The information posted in this release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by use of the words "may," "will," "should," "plans," "expects," "anticipates," "continue," "estimate," "project," "intend," and similar expressions. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, general economic and business conditions, effects of continued geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, delays in completing various engineering and manufacturing programs, changes in customer order patterns, changes in product mix, continued success in technological advances and delivering technological innovations, shortages in components, production delays due to performance quality issues with outsourced components, and various other factors beyond the Company's control.


To view the original version on PR Newswire, visit:


PR Newswire

Last updated on: 01/11/2016

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.